| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| norethisterone | Tablet, uncoated | 350 microgram | Current | Unavailable | Manufacturing | 22/11/2024 |
| isosorbide dinitrate | Tablet, uncoated | 5 mg | Current | Limited Availability | Manufacturing | 22/11/2024 |
| octreotide | Injection, solution | 50 microgram | Current | Unavailable | Manufacturing | 22/11/2024 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 22/11/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 22/11/2024 |
| methotrexate | Injection, solution | 100 mg/mL | Current | Unavailable | Manufacturing | 22/11/2024 |
| rosuvastatin calcium | Tablet, film coated | 10.42 mg | Anticipated | Available | Manufacturing | 22/11/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/11/2024 |
| clonazepam | Tablet, uncoated | .5 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/11/2024 |
| escitalopram oxalate | Tablet, film coated | 12.74 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 22/11/2024 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Current | Unavailable | Manufacturing | 22/11/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Limited Availability | Manufacturing | 22/11/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 10.341 mg~10 mg | Current | Unavailable | Manufacturing | 22/11/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~10.341 mg | Current | Limited Availability | Manufacturing | 22/11/2024 |
| dasatinib propylene glycol | Tablet, film coated | 81.2 mg | Current | Unavailable | Manufacturing | 22/11/2024 |
| Follitropin beta | Injection, solution | 833 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 22/11/2024 |
| Follitropin beta | Injection, solution | 833 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 22/11/2024 |
| clonazepam | Tablet, uncoated | .5 mg | Current | Limited Availability | Manufacturing | 22/11/2024 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Current | Limited Availability | Unexpected increase in consumer demand | 22/11/2024 |
| heparin sodium | Injection, solution | 10 IU/mL | Current | Unavailable | Manufacturing | 22/11/2024 |
| ezetimibe | Tablet | 10 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/11/2024 |
| oxazepam | Tablet, uncoated | 15 mg | Current | Unavailable | Manufacturing | 21/11/2024 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 21/11/2024 |
| esomeprazole magnesium dihydrate | Tablet, enteric coated | 21.75 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 21/11/2024 |
| esomeprazole | Capsule, enteric | 40 mg | Current | Limited Availability | Manufacturing | 21/11/2024 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Limited Availability | Manufacturing | 21/11/2024 |
| lacosamide | Tablet, film coated | 150 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 21/11/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Resolved | Available | Manufacturing | 21/11/2024 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.94 mg~20 mg | Current | Unavailable | Manufacturing | 21/11/2024 |
| oxazepam | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 21/11/2024 |
| gemfibrozil | Tablet, film coated | 600 mg | Current | Limited Availability | Manufacturing | 21/11/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 21/11/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Current | Limited Availability | Manufacturing | 21/11/2024 |
| moclobemide | Tablet, film coated | 150 mg | Current | Limited Availability | Manufacturing | 21/11/2024 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Anticipated | Available | Manufacturing | 20/11/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Manufacturing | 20/11/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 8 mg | Current | Limited Availability | Manufacturing | 20/11/2024 |
| nicotinic acid | Tablet, uncoated | 250 mg | Current | Unavailable | Manufacturing | 20/11/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.819 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 20/11/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 20/11/2024 |
| phentermine hydrochloride | Tablet, modified release | 49.7 mg | Resolved | Available | Manufacturing | 20/11/2024 |
| methotrexate | Tablet | 10 mg | Current | Unavailable | Manufacturing | 20/11/2024 |
| oxcarbazepine | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 20/11/2024 |
| balsalazide sodium | Capsule | 750 mg | Anticipated | Available | Manufacturing | 20/11/2024 |
| sevelamer hydrochloride | Tablet, film coated | 800 mg | Anticipated | Available | Manufacturing | 19/11/2024 |
| fluticasone furoate | Spray, suspension | 27.5 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 19/11/2024 |
| methotrexate | Injection, solution | 100 mg/mL | Resolved | Available | Manufacturing | 19/11/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Current | Limited Availability | Manufacturing | 19/11/2024 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Anticipated | Available | Manufacturing | 19/11/2024 |
| telmisartan~hydrochlorothiazide | Tablet, film coated | 80 mg~12.5 mg | Current | Unavailable | Manufacturing | 19/11/2024 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Current | Limited Availability | Manufacturing | 19/11/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 2 mg/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 19/11/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 19/11/2024 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Manufacturing | 19/11/2024 |
| ezetimibe | Tablet | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 19/11/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 19/11/2024 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 19/11/2024 |
| tadalafil | Tablet, film coated | 10 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Limited Availability | Manufacturing | 19/11/2024 |
| lorazepam | Tablet | 2.5 mg | Anticipated | Available | Manufacturing | 19/11/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| sodium chloride | Injection, intravenous infusion | 900 mg | Resolved | Available | Manufacturing | 19/11/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| morphine sulfate pentahydrate | Capsule, modified release | 120 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 19/11/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 19/11/2024 |
| oxycodone hydrochloride | Oral Liquid, solution | 1 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 19/11/2024 |
| alprostadil | Injection, powder for | 40 microgram/mL | Current | Unavailable | Manufacturing | 19/11/2024 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 18/11/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Resolved | Available | Manufacturing | 18/11/2024 |
| sodium polystyrene sulfonate | Powder | 999.3 mg/g | Resolved | Available | Manufacturing | 18/11/2024 |
| tacrolimus monohydrate | Capsule, hard | 1.022 mg | Current | Unavailable | Manufacturing | 18/11/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Anticipated | Available | Manufacturing | 18/11/2024 |
| carboplatin | Injection, solution | 450 mg | Current | Limited Availability | Manufacturing | 18/11/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Anticipated | Available | Manufacturing | 18/11/2024 |
| rizatriptan benzoate | Wafer | 14.53 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 18/11/2024 |
| rabeprazole sodium | Tablet, enteric coated | 20 mg | Anticipated | Available | Commercial Changes / Commercial viability | 18/11/2024 |
| citalopram hydrobromide | Tablet, film coated | 12.495 mg | Anticipated | Available | Manufacturing | 18/11/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Anticipated | Available | Manufacturing | 18/11/2024 |
| betaxolol hydrochloride | Eye Drops, solution | 5.6 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 18/11/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Current | Limited Availability | Manufacturing | 18/11/2024 |
| latanoprost~timolol maleate | Eye Drops, solution | .05 mg/mL~6.83 mg/mL | Anticipated | Available | Manufacturing | 18/11/2024 |
| pregabalin | Capsule, hard | 150 mg | Resolved | Available | Manufacturing | 18/11/2024 |
| mesalazine | Tablet, enteric coated | 1.6 g | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 18/11/2024 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 113.37 mg~1000 mg | Current | Limited Availability | Manufacturing | 18/11/2024 |
| nortriptyline | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 18/11/2024 |
| betaxolol hydrochloride | Eye Drops, solution | 5.6 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 18/11/2024 |
| finasteride | Tablet, film coated | 1 mg | Anticipated | Available | Unexpected increase in consumer demand | 15/11/2024 |
| dutasteride~tamsulosin hydrochloride | Capsule, modified release | 500 microgram~400 microgram | Current | Limited Availability | Manufacturing | 15/11/2024 |
| Somatropin | Injection, powder for | 12 mg/mL | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 15/11/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 15/11/2024 |
| exemestane | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 15/11/2024 |
| metoprolol succinate | Tablet, modified release | 95 mg | Anticipated | Available | Manufacturing | 15/11/2024 |
| metoprolol succinate | Tablet, modified release | 47.5 mg | Anticipated | Available | Manufacturing | 15/11/2024 |
| entecavir | Tablet, film coated | .5 mg | Anticipated | Available | Manufacturing | 15/11/2024 |
| esomeprazole | Capsule, enteric | 20 mg | Anticipated | Available | Manufacturing | 15/11/2024 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 15/11/2024 |
| indometacin | Capsule, hard | 25 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 15/11/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Manufacturing | 15/11/2024 |
| esomeprazole sodium | Injection, powder for | 42.5 mg | Anticipated | Available | Manufacturing | 15/11/2024 |
| prazosin hydrochloride | Tablet, uncoated | 1.095 mg | Anticipated | Available | Unexpected increase in consumer demand | 14/11/2024 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Unavailable | Manufacturing | 14/11/2024 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 14/11/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 14/11/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Anticipated | Available | Manufacturing | 14/11/2024 |
| tenofovir disoproxil maleate | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 14/11/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Resolved | Available | Manufacturing | 14/11/2024 |
| carmustine | Injection, powder for | 100 mg | Resolved | Available | Manufacturing | 14/11/2024 |
| chloramphenicol | Eye Drops, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 14/11/2024 |
| thiotepa | Injection, powder for | 15 mg | Anticipated | Available | Unexpected increase in consumer demand | 14/11/2024 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 14/11/2024 |
| verapamil hydrochloride | Tablet, modified release | 180 mg | Current | Unavailable | Manufacturing | 14/11/2024 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 14/11/2024 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Current | Unavailable | Manufacturing | 14/11/2024 |
| amoxicillin sodium | Injection, powder for | 1060 mg | Current | Limited Availability | Manufacturing | 14/11/2024 |
| pravastatin sodium | Tablet, uncoated | 40 mg | Current | Unavailable | Manufacturing | 14/11/2024 |
| HPV Type 16 L1 Protein~HPV Type 18 L1 Protein | Injection, suspension | 20 microgram~20 microgram | Discontinued | Unavailable | Commercial Changes / Commercial viability | 13/11/2024 |
| heparin sodium | Injection, solution | 5000 IU/mL | Current | Limited Availability | Unexpected increase in consumer demand | 13/11/2024 |
| clopidogrel besilate | Tablet, film coated | 112.1 mg | Anticipated | Available | Manufacturing | 13/11/2024 |
| carbamazepine | Tablet, modified release | 200 mg | Current | Unavailable | Manufacturing | 13/11/2024 |
| prazosin hydrochloride | Tablet, uncoated | 1.1 mg | Current | Unavailable | Manufacturing | 13/11/2024 |
| prazosin hydrochloride | Tablet, uncoated | 2.2 mg | Current | Unavailable | Manufacturing | 13/11/2024 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Anticipated | Available | Manufacturing | 12/11/2024 |
| cisatracurium besilate | Injection, solution | 14.07 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 12/11/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Manufacturing | 12/11/2024 |
| atomoxetine hydrochloride | Capsule, hard | 114 mg | Anticipated | Available | Manufacturing | 12/11/2024 |
| prasugrel | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 12/11/2024 |
| sitagliptin fumarate | Tablet, film coated | 32.124 mg | Current | Limited Availability | Manufacturing | 12/11/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Manufacturing | 12/11/2024 |
| primidone | Tablet, uncoated | 250 mg | Resolved | Available | Manufacturing | 11/11/2024 |
| topiramate | Tablet, film coated | 100 mg | Anticipated | Available | Manufacturing | 11/11/2024 |
| topiramate | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 11/11/2024 |
| tramadol hydrochloride | Tablet, modified release | 200 mg | Anticipated | Available | Manufacturing | 11/11/2024 |
| metoprolol succinate | Tablet, modified release | 47.5 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| metoprolol succinate | Tablet, modified release | 95 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| fluconazole | Capsule, hard | 200 mg | Resolved | Available | Manufacturing | 11/11/2024 |
| mycophenolate sodium | Tablet, enteric coated | 384.7 mg | Current | Unavailable | Manufacturing | 11/11/2024 |
| alprostadil | Injection, powder for | 20 microgram/mL | Resolved | Available | Manufacturing | 11/11/2024 |
2024年11月25日